Presentations & Publications

Our Library on T Cell-based Immunotherapies for Cancer and Infectious Diseases

HBV
HPV
Cancer
Other

2026

Publication –

Frontiers in Bioengineering and Biotechnology

Haut LH, et al

Upstream process optimization and its critical role in chimpanzee adenoviral vector clinical drug development: lessons learned from VRON-0200 manufacturing
Publication –

Discover Medicine

Crespi A, et al

Benefit-risk considerations of immunotherapy in chronic hepatitis B
Publication –

The Lancet Microbe

Gane EJ & Wong GLH, et al

VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trial
Oral –

EASL 2026

Gane EJ, et al

A single VRON-0200 prime dose, followed by a monthly antiviral combination regimen, resulted in rapid, profound, and durable HBsAg declines in chronically hepatitis B infected patients
Poster –

ASGCT 2026

MacDonald P, et al

Anti-vector neutralizing antibody responses observed and sustained following prime-vaccination with VRON-0200 chimpanzee adenoviral vectors in adults with chronic HBV(CHB) infection on nucleos(t)ide therapy: exploratory analysis from a phase 1b study
Oral –

APASL 2026

Currie SL, et al

A single VRON-0200 prime dose induced sustained and/or continued HBsAg declines up to one-year post dosing, and rapid HBsAg declines with addition of antiviral agents, in chronically HBV-infected patients
Poster –

CROI 2026

Currie SL, et al

VRON-0200 Induced Broad and Sustained Anti-HBV Immunity in Chronically HBV-Infected Patients

2025

Oral –

AASLD 2025

Wong GL, et al.

HBsAg declines observed with VRON-0200 alone are rapidly enhanced with the addition of combination antiviral therapies: results from a Phase 1b study for functional cure in chronically HBV-infected patients
Poster –

EASL 2025

Gane EJ, et al.

Rapid HBsAg declines and HBsAb seroconversion observed with a single dose of VRON-0200 plus Tobevibart and Elebsiran: preliminary results of a VRON-0200 combination treatment from a Phase 1b study for functional cure in chronically HBV-infected patients
Poster –

EASL 2025

Gane EJ, et al.

HBsAg declines, and T cell increases, observed in CHB patients: Interim results from P1b trial of VRON-0200, a novel checkpoint modifier, following prime only, and prime and boost dosing
Oral –

APASL 2025

Wong GL, et al.

HBsAg Declines and Immune Responses Following a Single Dose of VRON VRON-0200: Interim Results from a Phase1B Study for HBV Functional Cure in Chronic HBV HBV-Infected Patients

2024

Poster –

AASLD 2024

Wong GL, et al.

Positive clinical and immune responses following a single dose of VRON-0200: Interim results from a Phase1b study for HBV functional cure in chronic HBV-infected patients
Oral –

GIHEP 2024

Luber A, et al.

The potential role for a novel class, a Checkpoint Modifier, in the functional cure of CHB: the science and clinical data from VRON-0200
Publication –

Vaccines

Mohammadi M, et al.

Preclinical Immunogenicity and Efficacy Studies for Therapeutic Vaccines for Human Papillomavirus-Type-16-Associated Cancer
Poster –

EASL 2024, Poster # LBP-018

Gane EJ, et al.

Promising first-in-human, first-in-class, Phase 1b immunogenicity data of VRON-0200, a novel checkpoint modifier containing immunotherapy, for HBV functional cure
Oral –

APASL 2024, Oral # O-0138

Wong, GL et al.

First-in-Human, First-in-Class, Phase 1B Preliminary Safety Data of VRON-0200, a Novel Checkpoint Modifier Containing Immunotherapy, for HBV Functional Cure

2023

Poster –

SITC 2023, Poster #454

Currie S, et al.

Checkpoint Modification of Early T cell Activation Provides Enhanced Anti-Tumor Activity and Survival Benefits in a Fast-Growing Preclinical Tumor Challenge Model
Poster –

EASL 2023, Poster #TOP-107

Ertl HCJ, et al.

Intrahepatic CD8+ T cells correlate with significant declines in HBV viral load and S antigen following a single vaccination with VRON-0200 in an AAV mouse model
Poster –

ESMO TAT 2023, Poster #36P

Currie S, et al.

Therapeutic Vaccination With HPV-16 Oncoproteins Fused Into a Checkpoint Modifier of Early T-cell Activation Protects Against HPV-associated Tumors in a Preclinical Model

2022

Oral –

ID Week 2022, Oral #869

Ertl HCJ, et al.

Novel checkpoint modifier lowers T cell activation threshold and enhances and broadens vaccine-induced responses to chronic viral infections
Publication –

Front Immunol, DOI: 10.3389/fimmu.2022.985382

Ertl HCJ, et al.

Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health
Publication –

Front Public Health, DOI: 10.3389/fpubh.2022.929445

Ertl HCJ, et al.

Back to the future: Can vaccines win the long-term fight against COVID-19?
Oral –

ASGCT, Abstract #0490

Luber A, et al.

Novel Early Checkpoint Modifier Demonstrates Broadened and Enhanced CD8+ T Cell Responses Across Multiple Preclinical Studies
Oral –

APASL, Abstract #OP-0685

Hasanpourghadi M, et al.

Preclinical Immunogenicity and Efficacy of VRON-0200: A Novel Therapeutic Vaccine for Potential Functional Cure Therapies in Patients with Chronic HBV
Poster –

ESMO TAT, Abstract #143

Luber A, et al.

Checkpoint Modification of BTLA-HVEM-LIGHT Signaling by HSV-1 Glycoprotein D (gD) Improves Vaccine-Induced CD8 T Cell Responses in Pre-clinical Cancer Models
Publication –

BioRxiv,  DOI: 10.1101/2022.02.23.481620

Novikov M, et al.

Pre-clinical Testing of Two Serologically Distinct Chimpanzee-Origin Adenovirus Vectors Expressing Spike of SARS-CoV-2

2021

Publication –

Virol J, PMID: 34876153

Hasanpourghadi M, et al.

Hepatitis B virus polymerase-specific T cell epitopes shift in a mouse model of chronic infection
Oral –

EASL, Abstract #OS-2478

Hasanpourghadi M, et al.

VRON-0200, a Therapeutic HBV Vaccine With an Intrinsic Checkpoint Inhibitor, Elicits Broad CD8+ T Cell Responses and Sustained Antiviral Declines in Preclinical Studies
Publication –

Trends Biochem Sci, PMID: 33810926

Hasanpourghadi M, et al.

COVID-19 Vaccines Based on Adenovirus Vectors

2020

Poster –

AASLD, Poster #0826

Hasanpourghadi M, et al.

Glycoprotein D, a Checkpoint Inhibitor of Early T cell Activation, Broadens HBV-specific CD8+ T cell Responses and Produces HBV Viral Load Declines in Preclinical Studies
Poster –

EASL, Poster #1303

Hasanpourghadi M, et al.

Immunogenicity and Efficacy of an HBV Vaccine with an Intrinsic Checkpoint Inhibitor
Poster –

ASCO-SITC Clinical Immuno-Oncology Symposium, Poster #71

Xiang ZQ, et al.

Glycoprotein D, a Checkpoint Inhibitor of Early T cell Activation, Improves Immunogenicity and Efficacy of an HPV-16 Vaccine in Preclinical Studies

2014

Publication –

J Immunol, PMID: 25024391

Zhang Y and Ertl HCJ

The Effect of Adjuvanting Cancer Vaccines with Herpes Simplex Virus Glycoprotein D on Melanoma-Driven CD8+ T Cell Exhaustion